US2015272932A1PendingUtilityA1

Use of analgesic potentiating compounds to potentiate the analgesic properties of an analgesic compound

62
Assignee: SCHABAR RES ASSOCIATES LLCPriority: Jan 4, 2008Filed: Apr 30, 2015Published: Oct 1, 2015
Est. expiryJan 4, 2028(~1.5 yrs left)· nominal 20-yr term from priority
Inventors:Bernard Schachtel
A61K 31/616A61K 31/167A61K 31/415A61K 31/485A61P 29/02A61P 25/04A61K 9/0053A61K 45/06A61K 31/426A61P 29/00A61K 31/192
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Described herein are methods for effectively and accurately measuring a patient response upon administration of one or more drugs to the patient. The methods are more sensitive than current methodologies. Also described herein are compositions comprising an analgesic and a sufficient amount of an antihistamine to enhance the analgesic properties of the analgesic. With respect to these compositions, the methods described herein are useful for evaluating qualities of pain, definite improvement, and one or more bodily functions of a subject afflicted with pain. The compositions described herein are useful in improving the quality of pain in a subject or a bodily function of a subject afflicted with pain or definite improvement of a subject afflicted with pain.

Claims

exact text as granted — not AI-modified
What is claimed: 
     
         1 . A dose composition comprising (i) an analgesic effective amount of a compound selected from the group consisting of naproxen and the pharmaceutically acceptable salt thereof at a dosage from 100 mg to 900 mg per dose composition, and (ii) an analgesic potentiating amount of a compound selected from the group consisting of nizatidine and the pharmaceutically effective salt or isomer thereof at a dosage from 10 mg to 200 mg per dose composition,
 wherein said dose composition comprises an admixture of (i) and (ii), wherein the dose composition does not have an enteric coating, and   wherein said naproxen or the pharmaceutically acceptable salt thereof and said nizatidine or the pharmaceutically acceptable salt or isomer thereof provides an enhanced analgesic response compared to the same dosage strength of said naproxen or the pharmaceutically acceptable salt thereof in the absence of said nizatidine or the pharmaceutically acceptable salt or isomer thereof.   
     
     
         2 . The composition of  claim 1 , wherein said analgesic compound defined in (i) is 100 mg to 300 mg naproxen or the pharmaceutically acceptable salt thereof per dose composition. 
     
     
         3 . The composition of  claim 2 , wherein said analgesic potentiating compound defined in (ii) is 50 mg to 100 mg nizatidine or the pharmaceutically acceptable salt or isomer thereof per dose composition. 
     
     
         4 . The composition of  claim 2 , wherein said analgesic potentiating compound defined in (ii) is 10 mg to 50 mg nizatidine or the pharmaceutically acceptable salt or isomer thereof per dose composition. 
     
     
         5 . The composition of  claim 2 , wherein said analgesic potentiating compound defined in (ii) is 50 mg of nizatidine or the pharmaceutically acceptable salt or isomer thereof per dose composition. 
     
     
         6 . The composition of  claim 2 , wherein said analgesic potentiating compound defined in (ii) is 100 mg to 200 mg nizatidine or the pharmaceutically acceptable salt or isomer thereof per dose composition. 
     
     
         7 . The composition of  claim 2 , wherein said analgesic potentiating compound defined in (ii) is 150 mg of nizatidine or the pharmaceutically acceptable salt or isomer thereof per dose composition. 
     
     
         8 . The composition of  claim 1 , wherein said analgesic compound defined in (i) is 200 mg to 600 mg naproxen or the pharmaceutically acceptable salt thereof per dose composition. 
     
     
         9 . The composition of  claim 8 , wherein said analgesic potentiating compound defined in (ii) is 50 mg to 100 mg nizatidine or the pharmaceutically acceptable salt or isomer thereof per dose composition. 
     
     
         10 . The composition of  claim 8 , wherein said analgesic potentiating compound defined in (ii) is 10 mg to 50 mg nizatidine or the pharmaceutically acceptable salt or isomer thereof per dose composition. 
     
     
         11 . The composition of  claim 8 , wherein said analgesic potentiating compound defined in (ii) is 50 mg of nizatidine or the pharmaceutically acceptable salt or isomer thereof per dose composition. 
     
     
         12 . The composition of  claim 8 , wherein said analgesic potentiating compound defined in (ii) is 100 mg to 200 mg nizatidine or the pharmaceutically acceptable salt or isomer thereof per dose composition. 
     
     
         13 . The composition of  claim 8 , wherein said analgesic potentiating compound defined in (ii) is 150 mg of nizatidine or the pharmaceutically acceptable salt or isomer thereof per dose composition. 
     
     
         14 . The composition of  claim 1 , wherein said analgesic compound defined in (i) is naproxen sodium. 
     
     
         15 . The composition of  claim 14 , wherein said naproxen sodium is 220 mg per dose composition. 
     
     
         16 . The composition of  claim 15 , wherein said analgesic potentiating compound defined in (ii) is 50 mg to 100 mg nizatidine or the pharmaceutically acceptable salt or isomer thereof per dose composition. 
     
     
         17 . The composition of  claim 15 , wherein said analgesic potentiating compound defined in (ii) is 10 mg to 50 mg nizatidine or the pharmaceutically acceptable salt or isomer thereof per dose composition. 
     
     
         18 . The composition of  claim 15 , wherein said analgesic potentiating compound defined in (ii) is 50 mg of nizatidine or the pharmaceutically acceptable salt or isomer thereof per dose composition. 
     
     
         19 . The composition of  claim 15 , wherein said analgesic potentiating compound defined in (ii) is 100 mg to 200 mg nizatidine or the pharmaceutically acceptable salt or isomer thereof per dose composition. 
     
     
         20 . The composition of  claim 15 , wherein said analgesic potentiating compound defined in (ii) is 150 mg of nizatidine or the pharmaceutically acceptable salt or isomer thereof per dose composition. 
     
     
         21 . The composition of  claim 14 , wherein said naproxen sodium is 200 mg to 600 mg per dose composition. 
     
     
         22 . The composition of  claim 21 , wherein said analgesic potentiating compound defined in (ii) is 50 mg to 100 mg nizatidine or the pharmaceutically acceptable salt or isomer thereof per dose composition. 
     
     
         23 . The composition of  claim 21 , wherein said analgesic potentiating compound defined in (ii) is 10 mg to 50 mg nizatidine or the pharmaceutically acceptable salt or isomer thereof per dose composition. 
     
     
         24 . The composition of  claim 21 , wherein said analgesic potentiating compound defined in (ii) is 50 mg of nizatidine or the pharmaceutically acceptable salt or isomer thereof dose composition. 
     
     
         25 . The composition of  claim 21 , wherein said analgesic potentiating compound defined in (ii) is 100 mg to 200 mg nizatidine or the pharmaceutically acceptable salt or isomer thereof per dose composition. 
     
     
         26 . The composition of  claim 21 , wherein said analgesic potentiating compound defined in (ii) is 150 mg of nizatidine or the pharmaceutically acceptable salt or isomer thereof per dose composition. 
     
     
         27 . The composition of  claim 1 , wherein said analgesic compound defined in (i) is naproxen. 
     
     
         28 . The composition of  claim 27 , wherein said naproxen is 200 mg per dose composition. 
     
     
         29 . The composition of  claim 27 , wherein said analgesic potentiating compound defined in (ii) is 50 mg to 100 mg nizatidine or the pharmaceutically acceptable salt or isomer thereof per dose composition. 
     
     
         30 . The composition of  claim 27 , wherein said analgesic potentiating compound defined in (ii) is 10 mg to 50 mg nizatidine or the pharmaceutically acceptable salt or isomer thereof per dose composition. 
     
     
         31 . The composition of  claim 27 , wherein said analgesic potentiating compound defined in (ii) is 50 mg of nizatidine or the pharmaceutically acceptable salt or isomer thereof dose composition. 
     
     
         32 . The composition of  claim 27 , wherein said analgesic potentiating compound defined in (ii) is 100 mg to 200 mg nizatidine or the pharmaceutically acceptable salt or isomer thereof per dose composition. 
     
     
         33 . The composition of  claim 27 , wherein said analgesic potentiating compound defined in (ii) is 150 mg of nizatidine or the pharmaceutically acceptable salt or isomer thereof per dose composition. 
     
     
         34 . The composition of  claim 1 , wherein the analgesic compound defined in (i) and nizatidine or the pharmaceutically acceptable salt or isomer thereof are incorporated into a polymeric matrix. 
     
     
         35 . The compositions of  claim 1 , wherein the composition comprises a solid dose composition.

Join the waitlist — get patent alerts

Track US2015272932A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.